Endocrine-Resistant HR-Positive Metastatic Breast Cancer — An Interview with Dr Hope S Rugo on Optimal Management

Research To Practice | Oncology Videos · Jul 29, 2025 · 27m

Featuring an interview with Dr Hope S Rugo, including the following topics:

Pharmacologic features of antibody-drug conjugates (ADCs) and implications for their efficacy and toxicity in HR-positive breast cancer (0:00)

Clinical and biological factors influencing the sequencing of approved ADCs for HR-positive and triple-negative metastatic breast cancer (4:03)

Management of common toxicities with approved ADCs (10:48)

Sacituzumab govitecan as first-line therapy for metastatic triple-negative breast cancer (18:17)

Trastuzumab deruxtecan in combination with pertuzumab as first-line therapy for…